Login to Your Account



ADC Therapeutics Getting $40M Investment

Astrazeneca Paying up to $440M for Payload Tech Firm Spirogen

By Nuala Moran
Staff Writer

Wednesday, October 16, 2013
LONDON – Astrazeneca plc is taking a giant stride into antibody-drug conjugates (ADCs), acquiring payload technology company Spirogen plc for $200 million in cash, with a further $240 million to come in potential development milestones.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription